Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish pharmaceutical company Allenex group has announced that its subsidiary AbSorber and EUROSTAM, an European Transplant Centers consortium, have been awarded a grant of €2.6m by European Commission (EC), as part of EC's 7th framework programme (FP7).
Subscribe to our email newsletter
According to the company, from the €2.6m grant it will receive €215.000, which would be used in its ongoing three year project of determining the clinical value of implementing a Europe-wide acceptable HLA mismatch program, which will aid in safer transplantations in highly sensitized patients all over Europe.
Under the project, AbSorber will use its newly developed The XM-ONE crossmatch test, which not only helps to detect the anti-endothelial antibodies, but also determines if the antibodies are complement fixing or non-complement fixing, which is another risk factor.
Th firm said it is also planning to develop a modified version of XM-ONE.
Allenex and AbSorber CEO Anders Karlsson said the firm is happy to team up with the EUROSTAM consortium
"This is a strong recognition of the product XM-ONE as well as the research and development done within AbSorber. It is encouraging for our development team to be recognized for the innovation of XM-ONE,"Karlsson added.
"We look forward to further develop XM-ONE into a transplantation product with a proven clinical value in cooperation with leading European transplantation centers."